Case comparison and literature review of glioblastoma: A tale of two tumors

Gustavo Mendez, Alp Ozpinar, Jeffrey Raskin, Sakir Gultekin, Donald (Don) Ross

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Diagnosis of glioblastoma multiforme (GBM) includes a heterogeneous group of tumors. We describe two cases with histopathologically and molecularly similar tumors, but very different outcomes. We attempt to illustrate the need for improved prognostic markers for GBM.

Case Description: Two patients with similar molecular profiles were retrospectively identified. The following markers were assessed: O6-methylguanine DNA methyltransferase (MGMT) methylation, isocitrate dehydrogenase (IDH) 1 and 2 status, epidermal growth factor receptor (EGFR) amplification, phosphatase and tensin homolog (PTEN) status, Ki-67, p53, and 1p/19q status. Each patient was assigned a Karnofsky performance score at presentation. Case 1 (62-year-old male) was a right temporal lobe glioblastoma with a molecular profile of amplified EGFR, normal PTEN, no IDH1/2 mutation, 28.7% MGMT promoter methylation, 5-20% Ki-67, 1p deletion, and 19q intact. The patient underwent resection followed by radiation therapy and 2 years of chemotherapy, and was asymptomatic and tumor free 5 years post diagnosis. Tumor eventually recurred and the patient expired 72 months after initial diagnosis. Case 2 (63-year-old male) was a right frontal white matter mass consistent with glioblastoma with a molecular profile of amplified EGFR, absent PTEN, no IDH1/2 mutation, 9.9% MGMT promoter methylation, 5-10% Ki-67, and 1p/19q status inconclusive. A radical subtotal resection was performed; however, 2 weeks later symptoms had returned. Subsequent imaging revealed a tumor larger than at diagnosis. The patient expired 3 months after initial diagnosis.

Conclusion: The need for formulating more robust means to classify GBM tumor subtypes is paramount. Standard histopathologic and molecular analyses are costly and did not provide either of these patients with a realistic appraisal of their prognosis. Individualized whole genome testing similar to that being reported for medulloblastoma and other tumors may be preferable to the array of tests as currently utilized.

Original languageEnglish (US)
Article number138034
JournalSurgical Neurology International
Volume5
Issue numberSupplement
DOIs
StatePublished - 2014

Fingerprint

Glioblastoma
Methyltransferases
Phosphoric Monoester Hydrolases
Epidermal Growth Factor Receptor
Neoplasms
Methylation
Isocitrate Dehydrogenase
Mutation
Medulloblastoma
DNA
DNA Methylation
Temporal Lobe
Radiotherapy
Genome
Drug Therapy
Tensins

Keywords

  • 1p/19q deletion
  • Epidermal growth factor receptor amplification
  • Glioblastoma
  • Isocitrate dehydrogenase1
  • Isocitrate dehydrogenase1 mutation
  • O6-methylguanine dna methyltransferase methylation and expression
  • Prognosis

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Case comparison and literature review of glioblastoma : A tale of two tumors. / Mendez, Gustavo; Ozpinar, Alp; Raskin, Jeffrey; Gultekin, Sakir; Ross, Donald (Don).

In: Surgical Neurology International, Vol. 5, No. Supplement, 138034, 2014.

Research output: Contribution to journalArticle

Mendez, Gustavo ; Ozpinar, Alp ; Raskin, Jeffrey ; Gultekin, Sakir ; Ross, Donald (Don). / Case comparison and literature review of glioblastoma : A tale of two tumors. In: Surgical Neurology International. 2014 ; Vol. 5, No. Supplement.
@article{b81bcd58a3f844fb987e11545707195b,
title = "Case comparison and literature review of glioblastoma: A tale of two tumors",
abstract = "Background: Diagnosis of glioblastoma multiforme (GBM) includes a heterogeneous group of tumors. We describe two cases with histopathologically and molecularly similar tumors, but very different outcomes. We attempt to illustrate the need for improved prognostic markers for GBM.Case Description: Two patients with similar molecular profiles were retrospectively identified. The following markers were assessed: O6-methylguanine DNA methyltransferase (MGMT) methylation, isocitrate dehydrogenase (IDH) 1 and 2 status, epidermal growth factor receptor (EGFR) amplification, phosphatase and tensin homolog (PTEN) status, Ki-67, p53, and 1p/19q status. Each patient was assigned a Karnofsky performance score at presentation. Case 1 (62-year-old male) was a right temporal lobe glioblastoma with a molecular profile of amplified EGFR, normal PTEN, no IDH1/2 mutation, 28.7{\%} MGMT promoter methylation, 5-20{\%} Ki-67, 1p deletion, and 19q intact. The patient underwent resection followed by radiation therapy and 2 years of chemotherapy, and was asymptomatic and tumor free 5 years post diagnosis. Tumor eventually recurred and the patient expired 72 months after initial diagnosis. Case 2 (63-year-old male) was a right frontal white matter mass consistent with glioblastoma with a molecular profile of amplified EGFR, absent PTEN, no IDH1/2 mutation, 9.9{\%} MGMT promoter methylation, 5-10{\%} Ki-67, and 1p/19q status inconclusive. A radical subtotal resection was performed; however, 2 weeks later symptoms had returned. Subsequent imaging revealed a tumor larger than at diagnosis. The patient expired 3 months after initial diagnosis.Conclusion: The need for formulating more robust means to classify GBM tumor subtypes is paramount. Standard histopathologic and molecular analyses are costly and did not provide either of these patients with a realistic appraisal of their prognosis. Individualized whole genome testing similar to that being reported for medulloblastoma and other tumors may be preferable to the array of tests as currently utilized.",
keywords = "1p/19q deletion, Epidermal growth factor receptor amplification, Glioblastoma, Isocitrate dehydrogenase1, Isocitrate dehydrogenase1 mutation, O6-methylguanine dna methyltransferase methylation and expression, Prognosis",
author = "Gustavo Mendez and Alp Ozpinar and Jeffrey Raskin and Sakir Gultekin and Ross, {Donald (Don)}",
year = "2014",
doi = "10.4103/2152-7806.138034",
language = "English (US)",
volume = "5",
journal = "Surgical Neurology International",
issn = "2152-7806",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "Supplement",

}

TY - JOUR

T1 - Case comparison and literature review of glioblastoma

T2 - A tale of two tumors

AU - Mendez, Gustavo

AU - Ozpinar, Alp

AU - Raskin, Jeffrey

AU - Gultekin, Sakir

AU - Ross, Donald (Don)

PY - 2014

Y1 - 2014

N2 - Background: Diagnosis of glioblastoma multiforme (GBM) includes a heterogeneous group of tumors. We describe two cases with histopathologically and molecularly similar tumors, but very different outcomes. We attempt to illustrate the need for improved prognostic markers for GBM.Case Description: Two patients with similar molecular profiles were retrospectively identified. The following markers were assessed: O6-methylguanine DNA methyltransferase (MGMT) methylation, isocitrate dehydrogenase (IDH) 1 and 2 status, epidermal growth factor receptor (EGFR) amplification, phosphatase and tensin homolog (PTEN) status, Ki-67, p53, and 1p/19q status. Each patient was assigned a Karnofsky performance score at presentation. Case 1 (62-year-old male) was a right temporal lobe glioblastoma with a molecular profile of amplified EGFR, normal PTEN, no IDH1/2 mutation, 28.7% MGMT promoter methylation, 5-20% Ki-67, 1p deletion, and 19q intact. The patient underwent resection followed by radiation therapy and 2 years of chemotherapy, and was asymptomatic and tumor free 5 years post diagnosis. Tumor eventually recurred and the patient expired 72 months after initial diagnosis. Case 2 (63-year-old male) was a right frontal white matter mass consistent with glioblastoma with a molecular profile of amplified EGFR, absent PTEN, no IDH1/2 mutation, 9.9% MGMT promoter methylation, 5-10% Ki-67, and 1p/19q status inconclusive. A radical subtotal resection was performed; however, 2 weeks later symptoms had returned. Subsequent imaging revealed a tumor larger than at diagnosis. The patient expired 3 months after initial diagnosis.Conclusion: The need for formulating more robust means to classify GBM tumor subtypes is paramount. Standard histopathologic and molecular analyses are costly and did not provide either of these patients with a realistic appraisal of their prognosis. Individualized whole genome testing similar to that being reported for medulloblastoma and other tumors may be preferable to the array of tests as currently utilized.

AB - Background: Diagnosis of glioblastoma multiforme (GBM) includes a heterogeneous group of tumors. We describe two cases with histopathologically and molecularly similar tumors, but very different outcomes. We attempt to illustrate the need for improved prognostic markers for GBM.Case Description: Two patients with similar molecular profiles were retrospectively identified. The following markers were assessed: O6-methylguanine DNA methyltransferase (MGMT) methylation, isocitrate dehydrogenase (IDH) 1 and 2 status, epidermal growth factor receptor (EGFR) amplification, phosphatase and tensin homolog (PTEN) status, Ki-67, p53, and 1p/19q status. Each patient was assigned a Karnofsky performance score at presentation. Case 1 (62-year-old male) was a right temporal lobe glioblastoma with a molecular profile of amplified EGFR, normal PTEN, no IDH1/2 mutation, 28.7% MGMT promoter methylation, 5-20% Ki-67, 1p deletion, and 19q intact. The patient underwent resection followed by radiation therapy and 2 years of chemotherapy, and was asymptomatic and tumor free 5 years post diagnosis. Tumor eventually recurred and the patient expired 72 months after initial diagnosis. Case 2 (63-year-old male) was a right frontal white matter mass consistent with glioblastoma with a molecular profile of amplified EGFR, absent PTEN, no IDH1/2 mutation, 9.9% MGMT promoter methylation, 5-10% Ki-67, and 1p/19q status inconclusive. A radical subtotal resection was performed; however, 2 weeks later symptoms had returned. Subsequent imaging revealed a tumor larger than at diagnosis. The patient expired 3 months after initial diagnosis.Conclusion: The need for formulating more robust means to classify GBM tumor subtypes is paramount. Standard histopathologic and molecular analyses are costly and did not provide either of these patients with a realistic appraisal of their prognosis. Individualized whole genome testing similar to that being reported for medulloblastoma and other tumors may be preferable to the array of tests as currently utilized.

KW - 1p/19q deletion

KW - Epidermal growth factor receptor amplification

KW - Glioblastoma

KW - Isocitrate dehydrogenase1

KW - Isocitrate dehydrogenase1 mutation

KW - O6-methylguanine dna methyltransferase methylation and expression

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84916209460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84916209460&partnerID=8YFLogxK

U2 - 10.4103/2152-7806.138034

DO - 10.4103/2152-7806.138034

M3 - Article

AN - SCOPUS:84916209460

VL - 5

JO - Surgical Neurology International

JF - Surgical Neurology International

SN - 2152-7806

IS - Supplement

M1 - 138034

ER -